Personalis (NASDAQ:PSNL) Shares Gap Down – Here’s Why

Shares of Personalis, Inc. (NASDAQ:PSNL) gapped down prior to trading on Monday . The stock had previously closed at $15.39, but opened at $14.56. Personalis shares last traded at $14.0830, with a volume of 3,002,381 shares trading hands.

Analyst Ratings Changes

A number of brokerages recently issued reports on PSNL. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. TD Cowen reissued a “buy” rating on shares of Personalis in a research report on Wednesday. Morgan Stanley lifted their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of Personalis in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Personalis presently has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Personalis Trading Down 14.3%

The business has a 50 day moving average of $10.94 and a 200-day moving average of $8.91. The firm has a market capitalization of $1.38 billion, a P/E ratio of -12.92 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. On average, analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling at Personalis

In related news, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $3,558,668.88. The trade was a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock valued at $5,599,929 in the last three months. 4.20% of the stock is owned by insiders.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently modified their holdings of the company. Aberdeen Group plc grew its stake in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Howland Capital Management LLC lifted its position in shares of Personalis by 65.5% in the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock worth $4,355,000 after purchasing an additional 216,442 shares in the last quarter. Next Century Growth Investors LLC bought a new stake in shares of Personalis in the fourth quarter worth $4,970,000. D.A. Davidson & CO. acquired a new position in Personalis during the fourth quarter worth $1,158,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Personalis during the fourth quarter worth $2,308,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.